GenSight Biologics successfully raises €25 million in an oversubscribed private placement with US and European institutional investors

GenSight Biologics launches a capital increase of approximately €25 million by means of an accelerated bookbuilding process

GenSight Biologics Reports Cash Position as of September 30, 2020 and Provides Operational Update

HealthTech Innovation Days (HTID®), Paris, France & Virtual Conference

Chardan 4th Annual Genetic Medicines Conference – Virtual

H.C. Wainwright 22nd Annual Global Investment Conference – Virtual Conference

GenSight Biologics draws down the €4 million second tranche of bonds from Kreos Capital

GenSight Biologics Reports Interim Financial Results for the First Half of 2020 and Provides Operational Update

GenSight Biologics obtains a €7m non-dilutive loan and renegotiates the bond agreement with Kreos Capital extending runway to mid-2021

GenSight Biologics Reports Cash Position as of March 31, 2020 and Provides Operational Update